Ulm Michael, Ramesh Arvind V, McNamara Keely M, Ponnusamy Suriyan, Sasano Hironobu, Narayanan Ramesh
University of Tennessee Health Science Center, Memphis, Tennessee, USA.
West Cancer Center, Memphis, Tennessee, USA.
Endocr Connect. 2019 Feb 1;8(2):R10-R26. doi: 10.1530/EC-18-0425.
Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.
激素依赖性癌症影响着超过40万名男性和女性，仅在美国，这些癌症导致的死亡总数就超过10万例。得益于在分子水平上对这些癌症认识的进步以及几种改变疾病进程的疗法的发现，在过去十年中，这些癌症导致的死亡人数呈平稳甚至下降趋势。这些先进的疗法不仅能有效减缓激素依赖性癌症的生长，还能深入了解这些癌症如何变得难治并演变成一个完全不同的亚群。本综述总结了激素依赖性癌症目前的治疗趋势，重点关注前列腺癌、乳腺癌和卵巢癌。该综述讨论了目前正在使用的临床药物、正处于不同开发阶段的有前景的分子，并对未来十年治疗格局将如何转变做出了一些预测。
